

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/727,383	12/02/2003	Paula M. Jardieu	P0790C4D1C2	7551
9157 75	90 05/20/2004		EXAMINER	
GENENTECH, INC.			HADDAD, MAHER M	
1 DNA WAY SOUTH SAN FRANCISCO, CA 94080			ART UNIT	PAPER NUMBER
555111511111	14 11 (1000)		1644	
			DATE MAILED: 05/20/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/727,383	JARDIEU ET AL.				
Office Action Summary	Examiner	Art Unit				
	Maher M. Haddad	1644				
The MAILING DATE of this communication app		orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-20 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-20 are subject to restriction and/or	wn from consideration.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of: 1. Certified copies of the priority document of the priority document of the priority document of the priority document of the certified copies o	nts have been received. Its have been received in Applica Ority documents have been receiv Ority (PCT Rule 17.2(a)).	tion No ved in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summar Paper No(s)/Mail I	y (PTO-413) Date.				
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	es 🔲 station of Informal	Patent Application (PTO-152)				

Application/Control Number: 10/727,383

Art Unit: 1644

DETAILED ACTION

- 1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
 - I. Claims 1-14 and 16-17, drawn to a method for treating a LFA-1-mediated disorder in a mammal comprising administering an initial dosing of an anti-ICAM-1 antibody, classified in Class 424, subclass 152.1 and 172.1.
 - II. Claims 1-18 and 20, drawn to a method for treating a LFA-1-mediated disorder in a mammal comprising administering an initial dosing of an <u>anti-CD18 antibody</u>, classified in Class 424, subclass 152.1 and 172.1.
 - III. Claims 1-20, drawn to a method for treating a LFA-1-mediated disorder in a mammal comprising administering an initial dosing of an <u>anti-CD11a antibody</u>, classified in Class 424, subclass 152.1 and 172.1.
- 2. Groups I-III are different methods. A method of detecting and a method of treating differ with respect to ingredients, method steps, and endpoints; therefore, each method is patentably distinct.
- 3. These inventions are distinct for the reasons given above. Even though the classification is shared, a different field of search would be required based upon the structurally distinct products recited and the various methods of use comprising distinct method steps. Therefore restriction for examination purposes as indicated is proper.
- 4. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maher Haddad whose telephone number is (703) 306-3472. The examiner can normally be reached Monday through Friday from 8:00 AM to 4:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Maher Haddad, Ph.D. Patent Examiner Technology Center 1600 May 14, 2004

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600